<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746317</url>
  </required_header>
  <id_info>
    <org_study_id>GC-001US</org_study_id>
    <nct_id>NCT00746317</nct_id>
  </id_info>
  <brief_title>A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)</brief_title>
  <official_title>A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 Administered Weekly in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is studying the safety and best dose of GC33 in patients with advanced or&#xD;
      metastatic liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I open-label dose escalation study of GC33 in patients with advanced or&#xD;
      metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics,&#xD;
      and preliminary assessment of anti-tumor activity. Enrollment will proceed until a maximum&#xD;
      tolerated dose (MTD) and a recommended Phase II dose has been established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of escalating doses of GC33</measure>
    <time_frame>Continuously</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics of GC33</measure>
    <time_frame>Continuously</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform a preliminary assessment of anti-tumor activity of GC33</measure>
    <time_frame>Continuously</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Advanced or Metastatic HCC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC33</intervention_name>
    <description>IV administration at 4 escalating dose levels.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved&#xD;
             informed consent form&#xD;
&#xD;
          -  Male or female ≥ 18 years old.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  ECOG Performance Status of 0-1.&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma (without fibrolamellar subtype).&#xD;
&#xD;
          -  Not a candidate for curative treatments.&#xD;
&#xD;
          -  Child-Pugh A or B.&#xD;
&#xD;
          -  Hematological, Biochemical and Organ Function:&#xD;
&#xD;
               -  AST (SGOT): ≤ 5.0 × ULN&#xD;
&#xD;
               -  ALT (SGPT): ≤ 5.0 × ULN&#xD;
&#xD;
               -  Total Bilirubin: ≤ 3.0 × ULN&#xD;
&#xD;
               -  Platelets: ≥ 50,000/μL&#xD;
&#xD;
               -  Absolute Neutrophil Count: ≥ 1,500/μL&#xD;
&#xD;
               -  Serum creatinine: ≤ 2.0 × ULN&#xD;
&#xD;
               -  PT-INR: ≤ 2.0,&#xD;
&#xD;
          -  Ability to provide a tumor tissue sample either by:&#xD;
&#xD;
               -  a sample obtained within 3 months prior to informed consent for HCC diagnosis.&#xD;
                  Resection samples are not acceptable.&#xD;
&#xD;
               -  undergo a biopsy to confirm HCC diagnosis&#xD;
&#xD;
          -  At least one measurable lesion based on Response Evaluation Criteria In Solid Tumors&#xD;
             criteria.&#xD;
&#xD;
        (Extension Phase)&#xD;
&#xD;
          -  Signed written Institutional Review Board (IRB)/Ethical Committee (EC) approved&#xD;
             informed consent form.&#xD;
&#xD;
          -  Male or female ≥ 18 years old.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  ECOG Performance Status of 0-1.&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma (without fibrolamellar subtype).&#xD;
&#xD;
          -  Not a candidate for curative treatments.&#xD;
&#xD;
          -  Child-Pugh A.&#xD;
&#xD;
          -  Hematological, Biochemical and Organ Function:&#xD;
&#xD;
               -  AST (SGOT): ≤ 5.0 × ULN&#xD;
&#xD;
               -  ALT (SGPT): ≤ 5.0 × ULN&#xD;
&#xD;
               -  Total Bilirubin: ≤ 3.0 × ULN&#xD;
&#xD;
               -  Platelets: ≥ 50,000/μL&#xD;
&#xD;
               -  Absolute Neutrophil Count: ≥ 1,500/μL&#xD;
&#xD;
               -  Serum creatinine: ≤ 2.0 × ULN&#xD;
&#xD;
               -  PT-INR: ≤ 2.0&#xD;
&#xD;
          -  IHC confirmed GPC3-positive HCC tumor tissue. Tumor tissue sample may be provided by:&#xD;
&#xD;
               -  A formalin fixed paraffin embedded block sample within 12 months prior to&#xD;
                  informed consent for HCC diagnosis;&#xD;
&#xD;
               -  Unstained slides obtained within 3 months prior to informed consent for HCC&#xD;
                  diagnosis;&#xD;
&#xD;
               -  Undergo biopsy to confirm GPC3-positive HCC.&#xD;
&#xD;
               -  Resection samples are not acceptable.&#xD;
&#xD;
          -  At least one measurable lesion based on Response Evaluation Criteria In Solid Tumors&#xD;
             criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh C.&#xD;
&#xD;
          -  Pregnant or lactating women or women of child-bearing potential and men of&#xD;
             childbearing potential not willing to use effective means of contraception.&#xD;
&#xD;
          -  Patients known to be positive for Human immunodeficiency virus infection.&#xD;
&#xD;
          -  Active infectious diseases requiring treatment except for hepatitis B and C.&#xD;
&#xD;
          -  Other malignancies within the last 5 years.&#xD;
&#xD;
          -  History of transplantation (organ, bone marrow transplantation,peripheral blood stem&#xD;
             cell transplantation, etc.).&#xD;
&#xD;
          -  Patients with significant concomitant disease determined by the investigator to be&#xD;
             potentially aggravated by the investigational drug.&#xD;
&#xD;
          -  Patients with brain metastases, other central nervous system or other psychiatric&#xD;
             disease.&#xD;
&#xD;
          -  Patients who received major surgery, local therapy for HCC, chemotherapy,&#xD;
             radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4&#xD;
             weeks prior to Day 1.&#xD;
&#xD;
          -  Patients who received the following treatments within 2 weeks prior to Day1:&#xD;
&#xD;
               -  Anticoagulant or thrombolytic agents for therapeutic purposes.&#xD;
&#xD;
               -  Systemic anti-viral therapy for hepatitis C/cirrhosis.&#xD;
&#xD;
               -  Blood transfusion&#xD;
&#xD;
          -  History of hypersensitivity to similar agents.&#xD;
&#xD;
          -  Patient is unable to comply with the requirements of the protocol and/or follow-up&#xD;
             procedures.&#xD;
&#xD;
        (Extension Phase)&#xD;
&#xD;
          -  Child-Pugh B or C.&#xD;
&#xD;
          -  Pregnant or lactating women or women of child-bearing potential and men of&#xD;
             childbearing potential not willing to use effective means of contraception.&#xD;
&#xD;
          -  Patients known to be positive for Human immunodeficiency virus infection.&#xD;
&#xD;
          -  Active infectious diseases requiring treatment except for hepatitis B and C.&#xD;
&#xD;
          -  Other malignancies within the last 5 years.&#xD;
&#xD;
          -  History of transplantation (organ, bone marrow transplantation, Peripheral blood stem&#xD;
             cell transplantation, etc.).&#xD;
&#xD;
          -  Patients with significant concomitant disease determined by the investigator to be&#xD;
             potentially aggravated by the investigational drug.&#xD;
&#xD;
          -  Patients with brain metastases, other central nervous system or other psychiatric&#xD;
             disease.&#xD;
&#xD;
          -  Patients who received major surgery, local therapy for HCC, chemotherapy,&#xD;
             radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4&#xD;
             weeks prior to Day 1.&#xD;
&#xD;
          -  Patients who received the following treatments within 2 weeks prior to Day 1:&#xD;
&#xD;
               -  Anticoagulations or thrombolytic agents for therapeutic purposes.&#xD;
&#xD;
               -  Systemic anti-viral therapy for hepatitis C/cirrhosis.&#xD;
&#xD;
               -  Blood transfusion&#xD;
&#xD;
          -  History of hypersensitivity to similar agents.&#xD;
&#xD;
          -  Patient is unable to comply with the requirements of the protocol and/or follow-up&#xD;
             procedures.&#xD;
&#xD;
          -  IHC confirmed GPC3-negative HCC tumor tissue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshihiko Ohtomo</last_name>
    <role>Study Chair</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center at the Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute at the Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

